RB51脂多糖作为佐剂对HPV16 L1和HPV16 E7 DNA疫苗治疗效果的影响。
RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines.
作者信息
Shirmohammadi Masoumeh, Soleimanjahi Hoorieh, Kianmehr Zahra, Karimi Hesam, Kaboudanian Ardestani Susan
机构信息
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Biochemistry, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.
出版信息
Iran J Basic Med Sci. 2021 Jan;24(1):92-97. doi: 10.22038/ijbms.2020.51043.11608.
OBJECTIVES
Human papillomavirus (HPV) is a primary contributing agent of cervical cancer. Eradication of HPV-related infections requires therapeutic strategies. We used RB51 rough lipopolysaccharide (R-LPS) as an adjuvant along with two HPV16 therapeutic DNA vaccines, pcDNA3-E7 and pcDNA3-L1, for improving DNA vaccine efficacy.
MATERIALS AND METHODS
For evaluation of the LPS adjuvant efficacy in combination with DNA vaccines to induce cellular immune responses, C57BL/6 mice were immunized with the DNA vaccines, with or without R-LPS adjuvant. IFN-γ and IL-4 cytokines assay was carried out for assessment of cellular and humoral immune responses.
RESULTS
Findings indicated that vaccination with pcDNA3-E7 or pcDNA3-L1 alone could induce strong cellular immune responses, but stronger antigen-specific T-cell immune responses were shown by co-administration of HPV16 E7 and HPV16 L1 DNA vaccines along with R-LPS adjuvant.
CONCLUSION
Overall, R-LPS through enhancement of T-cell immune responses can be considered an efficient vaccine adjuvant in future studies and trials.
目的
人乳头瘤病毒（HPV）是宫颈癌的主要致病因素。根除HPV相关感染需要治疗策略。我们将RB51粗糙脂多糖（R-LPS）作为佐剂，与两种HPV16治疗性DNA疫苗pcDNA3-E7和pcDNA3-L1联合使用，以提高DNA疫苗的效力。
材料与方法
为评估LPS佐剂与DNA疫苗联合诱导细胞免疫反应的效力，对C57BL/6小鼠接种含或不含R-LPS佐剂的DNA疫苗，并进行IFN-γ和IL-4细胞因子检测，以评估细胞免疫和体液免疫反应。
结果
结果表明，单独接种pcDNA3-E7或pcDNA3-L1可诱导强烈的细胞免疫反应，但HPV16 E7和HPV16 L1 DNA疫苗与R-LPS佐剂联合使用时，显示出更强的抗原特异性T细胞免疫反应。
结论
总体而言，R-LPS通过增强T细胞免疫反应，在未来的研究和试验中可被视为一种有效的疫苗佐剂。
Zotero 插件